Latest & greatest articles for sofosbuvir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sofosbuvir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sofosbuvir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sofosbuvir

3. Sofosbuvir

Sofosbuvir Top results for sofosbuvir - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for sofosbuvir The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

5. Sovaldi - Sofosbuvir

Sovaldi - Sofosbuvir Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include post-authorization

Health Canada - Drug and Health Product Register2018

6. Ledispavir / sofosbuvir (Harvoni) - treatment of chronic hepatitis C (CHC) in adolescents

Ledispavir / sofosbuvir (Harvoni) - treatment of chronic hepatitis C (CHC) in adolescents Abbreviated Submission ledipasvir/sofosbuvir 90mg/400mg film-coated tablet (Harvoni ® ) SMC No 1343/18 Gilead Sciences 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) ledipasvir/sofosbuvir (Harvoni ® ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years. SMC restriction: genotype 1 and 4 CHC only. SMC has previously accepted ledipasvir/sofosbuvir for use in adults with genotype 1 and 4 CHC. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

Scottish Medicines Consortium2018

7. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt 29666174 2018 04 22 1468-3288 2018 Apr 17 Gut Gut Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. gutjnl-2017-315906 10.1136/gutjnl-2017-315906 We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone (...) and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 weeks of ledipasvir/sofosbuvir±ribavirin. Interferon treatment-experienced patients were randomised to receive 12 weeks of ledipasvir/sofosbuvir±ribavirin, while sofosbuvir-experienced

EvidenceUpdates2018

8. Hepatitis C: sofosbuvir + velpatasvir (Epclusa) represents an advance for some patients

Hepatitis C: sofosbuvir + velpatasvir (Epclusa) represents an advance for some patients Prescrire IN ENGLISH - Spotlight ''Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients'', 1 April 2018 {1} {1} {1} | | > > > Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic advance in the treatment of hepatitis C, especially in patients infected by a genotype 2 virus. But the uncertainty surrounding its adverse effects is unacceptable. Hepatitis C can cause complications such as cirrhosis and liver cancer. Treatment depends on the virus genotype, the severity

Prescrire2018

11. Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents

Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents Published 12 March 2018 Statement of Advice: sofosbuvir 400mg film-coated tablets (Sovaldi ® ) SMC No 1326/18 Gilead Sciences Ltd 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation sofosbuvir (Sovaldi ® ) is not recommended for use within NHS Scotland. Indication under review: In combination with other medicinal products for the treatment of chronic hepatitis C

Scottish Medicines Consortium2018

13. Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment

Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment Early and Late Changes in Natural Killer Cells in Response to Ledipasvir/Sofosbuvir Treatment Lucy Golden-Mason, 1 Rachel H. McMahan, 1 Michael S. Kriss, 1 Alexandra L. Kilgore, 2,3 Linling Cheng, 1 Rachael J. Dran, 1 Amanda Wieland, 1 and Hugo R. Rosen 1,4 Chronic hepatitis C virus (HCV) infection is characterized by dysregulated natural killer (NK) cell responses. NKs play a critical role (...) in achieving sustained responses to interferon (IFN)-a-based therapy. Rapid sustained HCV-RNA clearance is now achieved with direct-acting antivirals (DAAs). Studies of patients receiving ?rst-wave DAAs suggest NK functional restoration. Here, we investigate the effect of mainstream DAA treatment on NKs. We collected a prospective cohort of male HCV genotype 1-infected patients treated with ledipasvir/sofosbuvir (n 5 22). Peripheral blood was obtained at treatment start, week 2 (W2), W4, W8, and W12

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

14. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort Paul Kwo, 1 Michael W. Fried, 2 K. Rajender Reddy, 3 Consuelo Soldevila-Pico, 4 Saro Khemichian, 5 Jama (...) Darling, 2 Phillippe J. Zamor, 6 Andrew A. Napoli, 7 Beatrice Anduze-Faris, 7 and Robert S. Brown Jr. 8 We report the ?ndings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child-Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced ?brosis/cirrhosis. Patients had LLOQ at any posttreatment visit after HCV RNA 10

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

15. [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 (...) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir/velpatasvir/ voxilaprevir (chronische

Health Technology Assessment (HTA) Database.2018

16. [Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C) – benefit assessment according to §35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C (...) ) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V

Health Technology Assessment (HTA) Database.2018

17. [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to §35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit (...) assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55

Health Technology Assessment (HTA) Database.2018

18. sofosbuvir velpatasvir voxilaprevir (TBC)

sofosbuvir velpatasvir voxilaprevir (TBC) sofosbuvir velpatasvir voxilaprevir | CADTH.ca Find the information you need sofosbuvir velpatasvir voxilaprevir Generic Name: sofosbuvir velpatasvir voxilaprevir Brand Name: TBC Manufacturer: Gilead Sciences Canada, Inc. Indications: Hepatitis C, chronic Submission Type: New Combination Project Status: Pending Call For Patient Input: July 7, 2017 Patient Input Closed: August 28, 2017 Anticipated Date: August 4, 2017 Biosimilar: No Fee Schedule 1

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2018